Pushkal Garg M.D. — Chief Medical Officer at Alnylam Pharmaceuticals

Dr. Pushkal Garg, M.D. has been Chief Medical Officer of Alnylam Pharmaceuticals, Inc. since January 3, 2017. Dr. Garg served as Senior Vice President of Clinical Development at Alnylam Pharmaceuticals, Inc. from October 29, 2014 to January 3, 2017. He was responsible for managing the Alnylam's clinical research, clinical operations and biometrics functions. He has extensive experience in clinical development across a broad range of therapeutic areas. Dr. Garg has 15 years of experience in clinical drug development. He served as Vice President, Global Clinical Research, Immunoscience at Bristol-Myers Squibb (BMS). In this role he was responsible for strategic leadership of the Immunoscience franchise and the successful development of multiple clinical assets across immune-mediated diseases in the areas of rheumatology, gastroenterology, nephrology and transplantation. During his eight-year tenure at BMS, he was instrumental to the late-stage development and approval of Nulojix(R) (belatacept) for kidney transplant recipients and for supplementary biologics license applications (BLA) for Orencia(R) (abatacept) around the world. Previously, Dr. Garg was at Millennium Pharmaceuticals, where Dr. Garg worked in various roles of increasing responsibility, overseeing the clinical development of multiple small molecule and biologic therapeutics for the treatment of inflammatory disorders. He completed residency training in Internal Medicine at UCSF, was a fellow in the Robert Wood Johnson Clinical Scholars Program at Johns Hopkins University and served on the faculty of Harvard Medical School and the Brigham & Women's Hospital in Boston prior to joining industry. Dr. Garg received a Bachelor of Arts with high honors in Biochemistry from the University of California, Berkeley and an M.D. from the University of California, San Francisco.